IRIS
ZANGHI', AURORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.471
EU - Europa 1.274
AS - Asia 1.124
Continente sconosciuto - Info sul continente non disponibili 467
SA - Sud America 285
AF - Africa 25
OC - Oceania 8
Totale 4.654
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.423
SG - Singapore 519
IE - Irlanda 386
RU - Federazione Russa 280
BR - Brasile 240
IT - Italia 206
CN - Cina 205
HK - Hong Kong 145
VN - Vietnam 106
FR - Francia 88
DE - Germania 78
SE - Svezia 71
BD - Bangladesh 49
FI - Finlandia 48
GB - Regno Unito 36
CA - Canada 23
AR - Argentina 17
IN - India 17
TR - Turchia 17
NL - Olanda 15
MX - Messico 12
PL - Polonia 12
IQ - Iraq 11
EC - Ecuador 9
ES - Italia 8
AT - Austria 7
ID - Indonesia 7
IR - Iran 7
ZA - Sudafrica 7
AU - Australia 6
JP - Giappone 6
PK - Pakistan 6
BE - Belgio 5
CH - Svizzera 5
CL - Cile 5
EG - Egitto 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
HU - Ungheria 4
MA - Marocco 4
SA - Arabia Saudita 4
VE - Venezuela 4
AL - Albania 3
CO - Colombia 3
DZ - Algeria 3
PH - Filippine 3
PT - Portogallo 3
PY - Paraguay 3
RO - Romania 3
UZ - Uzbekistan 3
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
HN - Honduras 2
HR - Croazia 2
JO - Giordania 2
LT - Lituania 2
MD - Moldavia 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
TT - Trinidad e Tobago 2
UA - Ucraina 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
TO - Tonga 1
VC - Saint Vincent e Grenadine 1
Totale 4.189
Salva come PNG Salva come JPEG
Città #
San Jose 433
Dublin 385
Singapore 198
Ashburn 148
Hong Kong 140
Beijing 110
Chandler 87
Santa Clara 76
Council Bluffs 71
Nyköping 70
Lauterbourg 59
Columbus 48
Ho Chi Minh City 39
Princeton 39
Helsinki 34
Los Angeles 30
Munich 27
Wilmington 26
São Paulo 25
Dallas 22
Frankfurt am Main 21
Hanoi 19
Naples 19
Moscow 17
New York 16
Milan 14
Turku 14
London 13
Assago 12
Des Moines 11
Rome 11
Hillsboro 10
Rio de Janeiro 10
Warsaw 10
Nuremberg 9
Seattle 9
Bari 8
Falkenstein 8
Kocaeli 8
Phoenix 8
Chicago 7
Düsseldorf 7
Guangzhou 7
Belo Horizonte 6
Curitiba 6
San Francisco 6
Ankara 5
Biên Hòa 5
Brooklyn 5
Buffalo 5
Frattamaggiore 5
Mexico City 5
Montreal 5
Ottawa 5
Paris 5
Tehran 5
The Dalles 5
Thái Bình 5
Tokyo 5
Toronto 5
Washington 5
Alessandria 4
Cairo 4
Campinas 4
Cedar Knolls 4
Denver 4
Francavilla Fontana 4
Johannesburg 4
Long Beach 4
Ninh Bình 4
Orem 4
Quito 4
Reston 4
Ribeirão Preto 4
San José 4
San Severo 4
Sorocaba 4
Tsuen Wan 4
Ufa 4
Vienna 4
Anápolis 3
Atlanta 3
Brussels 3
Buenos Aires 3
Bắc Ninh 3
Can Tho 3
Caxias do Sul 3
Chennai 3
Contagem 3
Da Nang 3
Guarulhos 3
Haiphong 3
Jiaxing 3
Karachi 3
Las Vegas 3
Lisbon 3
Lucera 3
New Haven 3
Norwalk 3
Pittsburgh 3
Totale 2.564
Salva come PNG Salva come JPEG
Nome #
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 113
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 113
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 100
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 99
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 99
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 99
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 97
Can new chemical therapies improve the management of multiple sclerosis in children? 93
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 93
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 92
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 90
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 89
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 89
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 87
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 87
An update on the safety of treating relapsing-remitting multiple sclerosis 84
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 83
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 82
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 80
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 79
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 77
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 76
Management of dysphagia in multiple sclerosis: current best practice 75
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 74
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer 73
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 71
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 70
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 70
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 70
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 70
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 68
Myeloid-derived Suppressor Cells and Multiple Sclerosis 67
Palliative care in progressive multiple sclerosis 66
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 65
A multimodal approach to distinguish multiple sclerosis phenotypes at diagnosis using biomarker profiles 64
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 62
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 62
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 61
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 61
Monocytic myeloid derived suppressor cells in hematological malignancies 59
Neural precursor cells tune striatal connectivity through the release of IGFBPL1 58
Multiple sclerosis from onset to secondary progression: a 30-year Italian register study 57
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 57
Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype 56
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 56
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 56
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 56
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study 55
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 55
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 55
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 54
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 54
Switching therapy: how and why in a real word setting cohort of persons with multiple sclerosis in Catania 54
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 54
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 53
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 52
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 52
Real-world comparison of safety profile in two groups of relapsing remitting multiple sclerosis on dimethyl-fumarate and teriflunomide therapy: preliminary results of a multicenter, prospective study 51
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey 48
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 48
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series 45
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 44
null 43
New treatment targets in multiple sclerosis therapy 43
Pharmacoeconomics of synthetic therapies for multiple sclerosis 43
Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study 38
Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab 28
Cognitive and structural brain changes in ofatumumab-treated multiple sclerosis: A longitudinal study 22
Cortical Atrophy and Cognitive Outcomes in Relapsing MS Patients Treated With Ofatumumab: a Real-World Longitudinal Study 21
null 12
null 12
null 10
Making the invisible audible: a real-world connected speech study in myasthenia gravis 2
Multidomain Fatigue, Cognitive, and Quality of Life Observations in Generalized Myasthenia Gravis Under Ravulizumab: A Case Series 1
Totale 4.654
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.904
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.904
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022226 0 0 1 0 95 5 7 14 26 16 4 58
2022/2023722 60 18 39 47 14 44 2 37 413 19 17 12
2023/2024219 15 29 13 17 36 11 18 35 21 9 9 6
2024/20251.061 42 35 38 12 19 117 144 55 250 69 108 172
2025/20262.189 96 247 240 322 117 86 303 217 200 121 79 161
2026/2027207 65 142 0 0 0 0 0 0 0 0 0 0
Totale 4.654